复方樟柳碱联合葛根素治疗缺血性视神经视网膜脉络膜病变

Effects of compound anisodine and puerarin injection in treatment of ischemic optic neuropathy and choroidoretinopathy

目的:观察复方樟柳碱注射液联合葛根素注射液对缺血性视神经视网膜脉络膜病变的疗效。方法:采用随机研究方法,将缺血性视神经视网膜脉络膜病变的患者108例随机分为对照组(50例),治疗组(58例)。对照组采用妥拉苏林注射液25mg,治疗组采用复方樟柳碱注射液2mL,均做患眼颞侧浅动脉旁皮下注射,1次/d,疗程为30d。两组均联合葛根素注射液400mg静脉点滴共30d。以视力、视野、眼底改变为疗效判断指标。对照组与治疗组治疗前各项主要指标具有可比性(P>0.05)。结果:有效率治疗组88.9%,对照组49.1%,两者比较其差异有显著性意义(χ2检验,χ2=20.140,P<0.001)。结论:复方樟柳碱联合葛根素注射液对缺血性视神经视网膜脉络膜病变疗效显著。

AIM： To evaluate the effects of compound anisodine injection combined with puerarin injection in the treatment of ischemic optic neuropathy and choroidoretinopathy. METHODS： A random controlled study was performed on 108 patients （116 eyes）, who were assigned into two groups randomly： 50 patients （53 eyes） in control group and 58 patients （63 eyes） in treatment group. Compound anisodine 2ml was injected subcutaneously around superficial temporal artery to patients in treatment group once every day, and tolazoline 25mg was given in the same way to patients in control group for 30d. At the same time puerarin injection 400rag was given by intravenous drip to the two groups for 30d. Visual acuity, visual field and fundus condition were examined to evaluate the effects of treatment. The main subjects of the control and treatment group before treatment were comparable （P〉0.05）.RESULTS： The difference of effective rate between treatment group （88.9%） and control group （49.1%） was significant （x^2=20.140, P〈0.00]）. CONCLUSION： Compound anisodine and puerarin injection is an effective drug to treat ischemic optic neuropathy and choroidoretinopathy.